Korea to cover Pfizer's Xalkori; Botox wins another label expansion; Merck CEO Frazier elected PhRMA board chairman;

@FiercePharma: Shanghai Haohai Biological plans Hong Kong IPO to raise $263M. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI: 275 GSK jobs at risk with consumer health move from Pittsburgh. Some will get offers in New Jersey. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Bad news, Teva--Sandoz has an FDA nod for generic Copaxone. But when will it launch? Story | Follow @CarlyHFierce

> Korea's national health insurance will cover Pfizer ($PFE) cancer drug Xalkori. More

> Massachusetts' highest court has upheld a $63 million verdict against Johnson & Johnson ($JNJ) over claims the company failed to properly warn consumers about the dangers of Children's Motrin. More

> Actavis' ($ACT) Botox has won FDA approval for the treatment of upper limb spasticity in adults. Release

> Pfizer is joining New York Gov. Andrew Cuomo's visit to Cuba. Report

> Merck ($MRK) CEO Ken Frazier has been elected chairman of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA). More

> India's Glenmark Pharmaceuticals is raising $151 million through a preferential allotment to Singapore government-owned investment firm Temasek. Report

Medical Device News

@FierceMedDev: ICYMI: NEA-backed Cartiva raises $6M after a recent FDA nod, as it heads into a PMA review. Story | Follow @FierceMedDev

@VarunSaxena2: UPDATED: HeartWare device meets trial endpoint, but stroke data a big concern. ICYMI | Follow @VarunSaxena2

@EmilyWFierce: VisualDx sees big future for mobile diagnostic tool. FierceDiagnostics report | Follow @EmilyWFierce

> FDA approves first near vision correcting implant that doesn't require cataract surgery. More

> Endo settles more than 350 vaginal mesh suits. Article

> Report: Patterson Companies looking to shed rehab supply business. Story

Biotech News

@FierceBiotech: Roche bets $555M on an Indian biotech's immuno-oncology drug. News | Follow @FierceBiotech

@JohnCFierce: What's driving the massive social media campaign for Genervon's ALS drug? (Exaggerated claims and a false assumption). Editor's corner | Follow @JohnCFierce

> Biotech guru Neil Woodford lands $1.2B for new tech fund. Report

> Data in hand, Merck shoots for Keytruda approval for lung cancer. Item

> Ampio routed as lead osteoarthritis drug flunks a PhIII test. News

> Novartis' new CAR-T hopeful looks safe in an early solid tumor study. Article

Animal Health News

> Fears of dog flu epidemic spread as questions arise about vaccine's effectiveness. News

> UN restrictions on narcotic ketamine would impede veterinary practices, trade group argues. More

> FDA coordinates with pharma to address IV fluid shortage. Item

> Cannabis biscuits sell out as lobbyists push medical marijuana rights for pets. Story

> Nexvet regroups as key study on lead dog drug shows 'low probability' of success. Article

Biotech IT News

> Sanofi sues drug information startup over side effect info. Item

> Biopharma puts better use of existing data at top of R&D wish list. More

> Apple, IBM team up for Watson-fueled assault on health research. Article

> California starts statewide precision medicine initiative with Atul Butte at the helm. Story

> PatientsLikeMe adds AstraZeneca to growing list of big-name clients. Report

And Finally... Having both depression and Type 2 diabetes may increase patients' risk of developing dementia, new research shows. More

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.